Abstract: Whey derived from ordinary milk includes a bottom fraction including lactose and minerals, a middle fraction including lower molecular weight proteins, and a top fraction including higher molecular weight proteins. The top whey fraction includes a measurable but low level concentration of immunologically active immunoglobulin plus other pathogen specific antibodies. The whey is ultrafiltered through one or more different process steps to yield a filtered product having a concentration of immunologically active immunoglobulin of at least about seven percent of total solids. The filtered product is periodically tested to verify its activity to a specified microbe. The filtered product is orally administered in a therapeutically effective dose to an animal to treat a disease.

Abstract: The present invention deals with LHRH antagonists which possess improved water solubility and while having the high antagonist potency of the basic peptides, are free of the edematogenic effects. These compounds are highly potent in inhibiting the release of gonadotropins from the pituitary gland in mammals, including humans.The compounds of this invention are represented by the formulaX--R.sup.1 --R.sup.2 --R.sup.3 --Ser--Tyr--R.sup.6 --Leu--Arg--Pro--R.sup.10 --NH.sub.2whereinX is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, or H.sub.2 N--CO,R.sup.1 is D-- or L--Pro, D-- or L--.DELTA..sup.3 --Pro, D--Phe, D--Phe(4--H1), D--Ser, D--Thr, D--Ala, D--Nal(1) or D--Nal (2),R.sup.2 is D--Phe or D--Phe(4--C1)R.sup.3 is D--Trp, D--Phe, D--Pal(3), D--Nal(1) or D--Nal(2),R.sup.6 is D--Cit, D--Hci, D--Cit(Q) or D--Hci(Q) andR.sup.

Abstract: Trauma-associated sepsis is effectively treated using gamma interferon alone or in combination with an antibiotic.

Abstract: A method of producing a whey protein concentrate rich in immunoglobulins which comprises fractionating whey proteins into an immunoglobulin rich fraction and an immunoglobulin depleted fraction and concentrating at least the immunoglobulin rich fraction, in which either (i) a protein containing liquid selected from the group consisting of a whey, a liquid whey protein concentrate or a reconstituted whey protein concentrate powder is subjected to ultrafiltration through a membrane having a molecular weight cut-off of substantially 500,000 whereby to directly produce an immunoglobulin enriched concentrate together with fat, the permeate containing at least a major proportion of the remaining whey proteins, or (ii) a protein containing liquid selected from the group consisting of a whey, a liquid whey protein concentrate or a reconstituted whey protein concentrate powder is subjected to the action of an anion-exchange resin to produce an effluent, the whey proteins in which contain a higher proportion of immunog

Abstract: A peptide of the general formula:H-X-A-Ywherein A is a peptide fragment comprising 6 to 50 amino acids, X is a peptide fragment comprising 1 to 10 Lys, and Y is hydroxy or amino group, said peptide being capable of specifically binding to an antibody having a specificity against an adult T cell leukemia associated antigen, a reagent for measuring an antibody having a specificity against an adult T cell leukemia associated antigen which comprises the peptide, and an adsorbent for an antibody having a specificity against an adult T cell leukemia associated antigen which comprises the peptide immobilized on a carrier.

Abstract: The invention relates to a method for inducing the production of a milk anti-hypertensive factor in an animal, to a method for the isolation of said factor from the milk of said animal in a substantially pure form, and to the use of said factor to treat hypertension in humans and other animals, and to compositions containing the anti-hypertensive factor.

Abstract: The invention relates to peptide derivatives which are useful anticoagulant agents.

Abstract: A dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: A process for the preparation of tripeptides of the general formula IU-A-B-C-OH Iin which U denotes hydrogen or a urethane protective group and A, B and C denote amino acids, by reaction of a compound of the general formula IIU'-B-OH IIin which U' is a urethane protective group which can be eliminated by hydrogenolysis, with a compound of the general formula IIIH-C-OR IIIin which R denotes alkyl, by the PPA method, elimination of U', and reacting the resulting compound of the formula IVH-B-C-OR IVwith a compound of the formula VU-A-OH Vin the presence of propylphosphonic anhydride, and finally eliminating R enzymatically.

Abstract: A method of removing an antigenic substance from a fluid comprises(1) forming a ternary complex by the interaction of(a) the antigenic substance,(b) a first antibody which contains a kappa chain and which binds to the antigenic substance, and(c) a second antibody which binds to the kappa chain of the first antibody, said second antibody being immobilized on a solid phase carrier, and(2) separating the fluid from the solid phase carrier.

Abstract: Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.

Abstract: A number of novel antihemostatic peptides are claimed. Included among the antihemostatic peptides claimed are R-T-K-L-F-W-I-S-Y-S-D-G-D-Q, Y-S-D-G-D-Q-C, L-L-V-N-G-A-Q-L-C, C-F-D-K-I-K-N-W-R-N-L-I-A-V-L-G-E-H-D-L-S, F-D-K-I-K-N-W-R-N-L-I-A-V-L-G-E-H-D-L-S-E-H-D-G-D-E-Q-S-R-R-V-A-Q-V-I, L-G-E-H-D-L-S-E-H-D-G-D-E-Q-S-R-R-V-A-Q-V-I, A-V-L-G-E-H-D-L-S-E-H-D-G, V-R-F-S-L-V-S-G-W-G-Q, G-Q-L-L-D-R-G-A-T-A-L-E-L-M-V-L-N-V-P-R-L, A-G-Y-S-D-G-S-K-D-S-C, P-H-A-T-H-Y-R-G-T-W-Y-L-T-G-I and V-Y-T-R-V-S-Q-Y-I-E-W-L-Q-K-L and their analogues. The peptides are useful for inhibiting the formation of the Factor VII-tissue factor macromolecular complex of for inhibiting the activation of Factor X by Factor VII.

Abstract: A method for the prophylaxis or direct treatment of dermatitis including psoriasis which comprises administering to the site of the disease an effective amount of a corticosteroid and a company which inhibits mast cells or binds with their mediators.

Abstract: The present invention relates to a method of treating chronic fatigue syndrome not associated with an HIV infection. In the method of the present invention patients are administered a pharmaceutically acceptable carrier together with(1) a neuropsychiatrically effective amount of a linear peptide of formula (I):R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.6 (I)whereinR.sup.a is Ala, D-Ala or Cys-Ala-, andR.sup.6 is Thr, Thr-amide, Thr-Cys or Thr-Cys-amide,or a derivative of the peptide or a physiologically acceptable salt thereof; or(2) a neuropsychiatrically effective amount of a linear peptide of formula (II):R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II)whereinR.sup.1 is X-Y or Y when Y is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu-, and X is Cys;R.sup.2 is Thr-, Ser- or Asp;R.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp;R.sup.4 is Tyr; andR.sup.

Abstract: A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.

Abstract: The present specification describes a process by which a blood substitute (hereinafter referred to as "HemoSafe") is derived from uniformly stabilized monomers and polymers of deoxyhemoglobin in its tight (T) conformation, with oxygen affinity similar to that of human blood. Two classes of HemoSafe are derived respectively from animal-hemoglobin and human-hemoglobin. HemoSafe (animal) differs from HemoSafe (human) in that it is free of polymers in order to reduce potential immunogenicity if used in man. Both types of HemoSafe may be derived in the following manner. The stabilized deoxyhemoglobins are converted to their carbonmonoxy derivatives (CO-HemoSafe) which are then stable under pasteurization conditions to render them viral disease transmission-free. CO-HemoSafes are stable for 2 months at 56.degree. C. in either the solution or the freeze-dried state. For transfusion CO-HemoSafes are easily oxygenated under sterile conditions by photoconversion yielding oxy-HemoSafe.

Abstract: The invention relates to a method of diagnosing and treating individuals with diabetes or at risk to develop diabetes mellitus. In particular, gastric emptying determinations are used to assess risk. Risk or early symptoms associated with subsequent development of diabetes mellitus may be controlled or alleviated by delaying gastric emptying. Delay orThe Government may have certain rights in the invention pursuant to grant No. 2-S07-RR07187-11.

Abstract: A novel dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: The present invention relates to DTrp-Phe containing tripeptides and pharmaceuticals, which possess tachykinin antagonism activity as well as processes of making such peptides.

Abstract: This invention pertains to amino acids attached to a solid support in a racemization free manner and to a method of covalently linking amino acids to solid supports for use in solid phase peptide syntheses.